Uptake and Degradation of Tissue Plasminogen Activator in Rat Liver

Summary

The mechanism of uptake of tissue plasminogen activator (tPA) in rat liver was studied. Radio-iodinated tPA was removed from the circulation after intravenous administration in a biphasic mode. The initial half life, t_1/2(α), and the terminal phase, t_1/2(β), were determined to be 0.5 min and 7.5 min, resp. Separation of the liver cells by collagenase perfusion and density centrifugation, revealed that the uptake per cell was two to three times higher in the non-parenchymal cells than in the parenchymal cells.

Endocytosis of fluorescein isothiocyanate-labelled or ¹²⁵I-labelled tPA was studied in pure cultures of liver cells in vitro. Liver endothelial cells and parenchymal cells took up and degraded tPA. Endocytosis was more efficient in liver endothelial cells than in parenchymal cells, and was almost absent in Kupffer cells.

Competitivb inhibition experiments showing that excess unlabelled tPA could compete with the uptake and degradation of ¹²⁵I-tPA, suggested that liver endothelial cells and parenchymal cells interact with the activator in a specific manner. Endocytosis of trace amounts of ¹²⁵I-tPA in cultures of liver endothelial cells and parenchymal cells was inhibited by 50% in the presence of 19 nM unlabelled tPA. Agents that interfere with one or several steps of the endocytic machinery inhibited uptake and degradation of ¹²⁵I-tPA in both cell types.

These findings suggest that 1) liver endothelial cells and parenchymal cells are responsible for the rapid hepatic clearance of intravenously administered tPA; 2) the activator is taken up in these cells by specific endocytosis, and 3) endocytosed tPA is transported to the lysosomes where it is degraded.

Keywords

Tissue plasminogen activator - Liver cells - Endocytosis - Receptor - Clearance

• References

• 1 Hoylaerts M, Rijken DC, Linjen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin J Biol Chem 1982; 257: 2912
• 2 Carlin G, Einarsson M, Saldeen T. Tissue plasminogen activator effectively lyses intravascular fibrin deposits in the rat lung. In: Progress in Fibrinolysis Vol. VI.. Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. Churchill-Livingstone; Edinburgh: 1983: 471-474
• 3 Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-661
• 4 Nilsson S, Einarsson M, Ekvärn S, Häggroth L, Mattsson Ch. Turnover of tissue plasminogen activator in normal and hepatec-tomized rabbits. Thromb Res 1985; 39: 511-522
• 5 Wiman B, Mellbring G, Rånby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127: 279-288
• 6 Nilsson T, Wallén P, Mellbring G. In vivo metabolism of human tissue-type plasminogen activator. Scand J Haematol 1984; 33: 49-53
• 7 Verstraete M, Bory M, Erbel R, Lennane RJ, Mathey D, Michels HR, Schartle M, Uebis R, Bernard R, Browner RW, DeDono DP, Huhman W, Lubsen J, Meyer J, Rutsch W, Schmidt W, Essen vonR. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European cooperative study group for recombinant tissue-type plasminogen activator Lancet 1985; 01: 842-847
• 8 Passamini E. The TIMI study group. et al. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med 1985; 312: 932-936
• 9 Einarsson M, Brandt J, Kaplan L. Large-scale purification of human tissue-type plasminogen activator using monoclonal. Biochim Biophys Acta 1985; 830: 1-10
• 10 Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3α,6α-diphenyl-glycouril. Biochem Biophys Res Commun 1978; 80: 849-857
• 11 Häggroth L, Mattsson Ch, Felding P, Nilsson IM. Plasminogen activator inhibitors in plasma and platelets from patients with recurrent venous thrombosis and pregnant women. Thromb Res 1986; 241: 739-749
• 12 Smedsrød B, Pertoft H. Preparation of pure hepatocytes and reticuloendothelial cells in high yield from a single rat liver by means of Percoll centrifugation and selective adherence. J Leukocyte Biol 1985; 38: 213-230
• 13 Smedsrød B, Pertoft H, Eggertsen G, Sundström Ch. Functional and morphological characterization of pure Kupffer cells (KC) and liver endothelial cells (LEC) prepared by means of density separation in Percoll, and selective substrate adherence. Cell Tissue Res 1985; 241: 739-749
• 14 Smedsrød B, Einarsson M, Pertoft H. Tissue plasminogen activator is endocytosed by mannose and galactose receptors of rat liver cells. Thromb Haemostas 1988; 59: 480-484
• 15 Pertoft H, Smedsrød B. Separation and characterization of liver cells. In: Cell Separation, Methods and Selected Applications. Pretlow II TG, Pretlow TP. Academic Press; New York: 1987. Vol 4 1-24
• 16 Fuchs HE, Berger Jr H, Pizzo SV. Catabolism of human tissue plasminogen activator in mice. Blood 1985; 65: 539-544
• 17 Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982; 51: 531-554
• 18 Kirn A, Knook DL, Wisse E. Cells of the Hepatic Sinusoid. The Kupffer Cell Foundation; Rijswijk: 1986. Vol 1
• 19 Smedsrød B, Johansson S, Pertoft H. In vivo and in vitro studies on the uptake and degradation of soluble collagen al (I) chains in rat liver endothelial and Kupffer cells. Biochem J 1985; 228: 415-424
• 20 Smedsrød B, Kjellén L, Pertoft H. Endocytosis and degradation of chondroitin sulphate by liver endothelial cells. Biochem J 1985; 229: 63-71
• 21 Smedsrød B, Pertoft H, Eriksson S, Fraser JR E, Laurent TC. Studies in vitro on the uptake and degradation of sodium hyaluronate in rat liver endothelial cells. Biochem J 1984; 223: 617-626